| ●Editorial | Kurihara C | 683-4 | Full text | ||
| ●Paradigms shift of drug discovery, development and lifetime management (Part II) | |||||
| Original：Comparison of approval timing and changing process of labels of three new innovative antibody medicines originated in Japan with those of FDA and EMA |
Morimoto K，Kobayashi T， Shibata H，Ishii-Watabe A | 685-700 | Full text | ||
| ●The past, present and future of bioethics and research ethics (Part V) | |||||
| ・Articles | |||||
| Original：Application of public healthcare insurance system for the treatment of research-related injury |
Nabeoka Y，Kurihara C， Mimura M，et al． | 701-9 | Abstract | ||
| Ethics and regulation of military research involving human subjects (1) Agenda setting and analysis of related documents of the USA |
Nudeshima J | 711-25 | Abstract | ||
| ・Invited lecture | |||||
| “Teihousha”－The testimony of the whistle-blower of scientific misconduct of human cloning embryonic stem cell research in Korea: “Truth, easy to get buried” |
Ryu YJ （Interpretation into Japanese：Rhee Y． Organized by：Pharmaceutical Study Group） | 727-43 | Abstract | ||
| ・Translation | |||||
| International Ethical Guidelines for Health-related Research Involving Humans ※Original publication in English by CIOMS | Council for International Organizations of Medical Sciences（CIOMS） （Translation：Kurihara C，Saio T． Supervision：Watanabe H） | 745-862 | |||
| ●Instructions for authors［Japanese］ & ［English］ | 863-71 | Full text | |||
| ●Editor's note | Nudeshima J | 873 | Full text | ||